Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cytokine that controls the production and function of blood cells, is deregulated in clinical conditions such as rheumatoid arthritis and leukemia, yet offers therapeutic value for other diseases. Its receptors are heterodimers consisting of a ligand-specific a subunit and a bc subunit that is shared with the interleukin (IL)-3 and IL-5 receptors. How signaling is initiated remains an enigma. We report here the crystal structure of the human GM-CSF/GM-CSF receptor ternary complex and its assembly into an unexpected dodecamer or higher-order complex. Importantly, mutagenesis of the GM-CSF receptor at the dodecamer interface and functional studies reveal that dodecamer formation is required for receptor activation and signaling. This unusual form of receptor assembly likely applies also to IL-3 and IL-5 receptors, providing a structural basis for understanding their mechanism of activation and for the development of therapeutics.
INTRODUCTION
A common feature of cytokine receptor activation is ligandinduced receptor aggregation involving the homo or heterodimerization of two or more receptor components and their assembly into a fully functional signaling complex. Structural data for heterodimeric receptor families that utilize a common binding and signaling subunit such as the IL-2 and IL-6 receptor systems have provided unique insights into their functional activation (Boulanger et al., 2003; Wang et al., 2005; Stauber et al., 2006) . The GM-CSF, IL-3, and IL-5 family of receptors remains the last major group of class I hematopoietic receptor systems to be structurally and functionally elucidated.
The GM-CSF, IL-3, and IL-5 family of cytokines regulates the survival, proliferation, differentiation, and functional activation of hematopoietic cells (Guthridge et al., 1998) with GM-CSF also controlling dendritic cell (Mellman and Steinman, 2001) and T cell function (Barouch et al., 2002) , thus linking innate and acquired immunity. While on the one hand GM-CSF offers therapeutic promise to bolster antitumor immunity (Sun et al., 2002; Fleetwood et al., 2005) and innate immunity for the treatment of Crohn's disease (Korzenik et al., 2005) , on the other hand abnormalities in GM-CSF production or receptor function have been implicated in multiple pathologies such as rheumatoid arthritis (Cook et al., 2001) , juvenile myelomonocytic leukemia (Birnbaum et al., 2000) , chronic myelomonocytic leukemia (Ramshaw et al., 2002) , and alveolar proteinosis (Dirksen et al., 1998) . Furthermore, the GM-CSF receptor may also be important in the pathogenesis of chronic myeloid leukemia and myeloproliferative diseases by propagating survival and proliferation signals promoted by the abnormal expression of Bcr-Abl and JAK2 mutations, respectively (Wilson-Rawls et al., 1996; James et al., 2005) . The receptors for GM-CSF, IL-3, and IL-5 are expressed at very low levels (100-1000 per cell) on the surface of hematopoietic cells and comprise a cytokine-specific a subunit and the bc subunit that is common to all three receptors (Guthridge et al., 1998) . Each a subunit binds cytokine with low affinity (K D = 0.2-100 nM) but the presence of bc converts this to high affinity (K D = 100 pM) causing dimerization of both subunits and receptor activation (Stomski et al., 1996) . Structure-function studies of GM-CSF, IL-3, and IL-5 and their receptors have noted regions of importance for ligand binding and biological activity; however the composition, assembly, and underlying mechanisms of receptor activation have remained elusive.
Although GM-CSF receptor activation follows general rules that invoke receptor dimerization and tyrosine transphosphorylation of the cytoplasmic domains (Schlessinger, 2000) , it is not clear how this is achieved. The GM-CSF receptor does not have intrinsic tyrosine kinase activity but associates with the tyrosine kinase JAK2, which is required for bc transphosphorylation and the initiation of signaling and biological activity. The cytoplasmic domains of both GMRa and bc are essential for receptor activation (Sakamaki et al., 1992; Muto et al., 1995) , but it appears that mainly bc associates with JAK2 (Brizzi et al., 1994; Quelle et al., 1994; Lilly et al., 2001) . Since the crystal structure of isolated bc revealed a dimer in which the membrane-proximal domains were 120 Å apart (Carr et al., 2001 ), a distance too great to allow transphosphorylation of bc by their associated JAK2 kinases, it has remained an enigma how activation of the GM-CSF, IL-3, and IL-5 family of receptors could be achieved. We show here that the crystal structure of the GM-CSF ternary complex assembles into an unexpected dodecamer arrangement. Functional analyses show that this dodecamer or higher-order complex brings two bc dimers into close proximity and provides for the functional dimerization and activation of the GM-CSF receptor.
RESULTS
The Structure of the GM-CSF Receptor Complex Reveals a Hexameric Assembly We have determined the structure of the GM-CSF ternary complex revealing a 2:2:2 hexamer consisting of two bc chains, two GMRa chains, and two GM-CSF molecules (Figure 1 ). This differs from the 2:1:1 stoichiometry (2 bc: 1 GMRa: 1 GM-CSF) we observed in solution (McClure et al., 2003) . This is likely to be a result of differences in the total protein concentration at which the complex is formed as we observe a protein concentrationdependent shift in molecular weight and hence stoichiometry of GM-CSF receptor complex ( Figure S1 and Table S2 available online). The 2:1:1 complex probably represents a relatively stable intermediate in the assembly of higher-order 2:2:2 GM-CSF receptor complexes. The structure adopted by GM-CSF in the ternary complex appears very similar to the structure of the isolated cytokine (Rozwarski et al., 1996) . We also observe the same intertwined bc homodimer previously seen in the structure of the isolated bc subunit (Carr et al., 2001 ). In our case the dimer is generated by a crystallographic two-fold axis that runs through the center of the hexameric complex. A comparison of the bc chain in the complex compared to the structure of the isolated molecule (Carr et al., 2006) reveals that domain 4 has rotated 3 toward the crystallographic diad that runs through the center of the hexameric complex ( Figure S2 ). The hinge region about which the rotation has occurred is located close to domain 1 in the linker region connecting domains 3 and 4, although the conformation of the linker region closely resembles that seen in the isolated molecule. Each bc chain consists of two cytokine receptor homology modules (CRMs), which in turn consist of two fibronectin type III (FnIII) domains. The GMRa chain consists of an N-terminal ''knob'' domain followed by one CRM. However, we only observe good electron density for the C-terminal FnIII domain of GMRa (GMRa domain 2). Although the electron density for N-terminal FnIII domain (GMRa domain 1) is of poorer quality, it was sufficient to recognize core b sheet enabling a partial model to be built and refined.
GM-CSF Interactions with GMRa-Site 1 GM-CSF binds to the elbow region defined by domains 1 and 2 of GMRa, reminiscent of the binding mode seen in other class I cytokine receptors (Wells and de Vos, 1996) . There is a small interaction surface between GM-CSF and GMRa domain 2 of 240 Å 2 per molecule with a surface complementarity of 0.66, a value within the range of normal protein-protein interaction surfaces (Figure 2 , Site 1). Additional surface area would be provided by domain 1. The loop residues 241 to 251 and 299 to 305 of GMRa interact with residues 11 to 23 (helix A) and residues 112 to 118 (helix D) of the cytokine. This is consistent with mutagenesis studies showing that D112 of GM-CSF interacts with GMRa (Hercus et al., 1994b) and that GMRa residues Y248 and R302 are important for GM-CSF binding to GMRa (Rajotte et al., 1997; Haman et al., 1999) .
GM-CSF Interactions with bc-Site 2 Recruitment of bc to the GM-CSF:GMRa binary complex converts the GM-CSF binding to high affinity and leads to receptor activation (Hayashida et al., 1990; Bagley et al., 1997) . Surprisingly, our structure reveals a composite GM-CSF binding site at the elbow region between domain 1 (A-B and E-F loops) of one bc chain and domain 4 (B-C and F-G loops) of the second bc chain (Figure 2 , Site 2), an arrangement not seen previously in cytokine-cytokine receptor complex structures (see Discussion) . The involvement of these loops in cytokine binding is consistent with previous mutagenesis data (Lock et al., 1994; Woodcock et al., 1994 Woodcock et al., , 1996 Murphy et al., 2003) . The interaction at Site 2 buries 570 Å 2 of surface area per molecule with a surface complementarity value of 0.62. Helix A of GM-CSF nestles into a surface crevice of bc formed by the E-F loop (residues 100 to 107) of bc domain 1 and the B-C (residues 360 to 369) and F-G (residues 417 to 423) loops of domain 4 (Figure 2 ). All the loops of bc that interact with cytokine adopt conformations very similar to that seen in isolated bc. In bc domain 1, Y39 of the A-B loop forms pi-pi interactions with Y421 in the F-G loop of domain 4. Residues V104, V105, and T106 of the E-F loop of domain 1 nestle into a hydrophobic pocket formed by helices A and C of GM-CSF. The side chain of the adjacent F103 residue is sandwiched between E-F and A-B loops of domain 1 stabilizing the conformation of this region in the Site 2 interface. D107 potentially forms a salt bridge interaction with K72 of GM-CSF. Y365 and H367 of the B-C loop of domain 4 are positioned on either side of E21 of GM-CSF. In the F-G loop of bc domain 4, Y421 hydrogen bonds with E21 of GM-CSF (Figure 2 , Site 2). These observations are consistent with mutagenesis studies showing that the principal cytokine interaction with bc occurs through a conserved glutamate in helix A of GM-CSF (E21) (Lopez et al., 1992; Hercus et al., 1994a) , IL-3 (E22) (Barry et al., 1994) , or IL-5 (E13) (Tavernier et al., 1995) with E21 of GM-CSF making direct contact with bc (McClure et al., 2003) and with alanine substitution of bc at Y39, F103, Y365, H367, I368, or Y421 abolishing GM-CSF binding (Lock et al., 1994; Woodcock et al., 1994 Woodcock et al., , 1996 Murphy et al., 2003) . Phenylalanine substitution of Y421 ablates high-affinity binding of GM-CSF and IL-3 ( Figure S3 ), highlighting the importance of the phenolic hydroxyl group in ligand binding.
Interactions between GMRa and bc-Site 3 Domain 2 of GMRa forms an extensive interaction with domain 4 of bc resulting in 680 Å 2 of buried surface area per molecule with a surface complementary value of 0.52. The interface, involving residues 231, 232, 259, [266] [267] [268] [269] [270] [280] [281] [282] [283] [284] [285] [286] 353, [366] [367] [368] [369] [389] [390] [391] [392] [393] [394] [395] [396] [397] [398] [399] [400] , and 418 of bc, is predominantly hydrophobic with a rim of charged residues (Figure 2, Site 3). We previously reported two surface hydrophobic patches, denoted H1 and H2, in our crystal structure of bc domain 4 and speculated that they might be involved in interaction with other parts of bc and GMRa, respectively (Rossjohn et al., 2000) . The structure reported here shows that residues in H1 contact the A-B loop of bc domain 1 whereas residues of H2, located at the edge of the beta strands D and E of bc domain 4, are involved in the formation of the interface with GMRa. The Site 3 interface provides additional interacting surfaces between GMRa and bc, thereby enhancing the overall binding affinity of GM-CSF for its receptor.
The GM-CSF Receptor Complex Assembles into a Dodecamer
The crystal lattice generates an unexpected dodecamer complex, an assembly not previously observed in structures of cytokine receptor complexes, consisting of two hexameric complexes related by a crystallographic two-fold axis ( Figure 3A) . Intriguingly, the dodecamer assembles in a head-to-head orientation bringing the C-terminal tails of neighboring bc domain 4 0 s and GMRa domain 2 0 s into close proximity, suggesting a physiological relevance to the assembly ( Figure 3B ). The interaction surface, that we term Site 4, is large with 770 Å 2 being buried per hexamer with major contributions between bc domain 4 of each hexamer (520 Å 2 per molecule) and the rest contributed from an interaction between the GMRa of one hexamer and bc domain 4 of the other. The mostly polar interface involves residues 260 and 261 of GMRa and residues 346-354, 357, 359, 362, and 430-435 of bc with a high surface complementarity value of 0.63. The bc domain 4 dodecamer interface includes the mutated N-linked glycosylation site, N346Q. Complex sugar chains are readily accommodated at the interface with only the first couple of sugars emanating from N346 located at the interface while the rest protrude out into solution ( Figure S4 ).
Dodecamer Complex Provides a Mechanism of Activation for JAK2 Associated with bc
The JAK/STAT pathway is the principal signal transduction pathway used by cytokine receptors. JAK activation occurs by ligand-induced dimerization and transphosphorylation of receptor-bound JAK molecules that subsequently phosphorylate the receptor itself, STATs, and other signaling molecules recruited to the receptors (Rawlings et al., 2004) . JAK2 activation is a feature of GM-CSF receptor activation (Quelle et al., 1994; Watanabe et al., 1996) and plays a critical and nonredundant role in GM-CSF signaling Parganas et al., 1998) . Although JAK2 has been seen to specifically associate with bc (Brizzi et al., 1994; Soldi et al., 1997; Lilly et al., 2001) its association with GMRa is much less clear (Quelle et al., 1994) . This is an important point as the selective association of JAK2 with bc would support the notion that juxtaposition of neighboring bc domain 4 0 s as seen in the dodecamer complex (but not the hexameric complex) ( Figure 3B ) would be required for JAK2 transphosphorylation and subsequent receptor activation.
First, we coimmunoprecipitated JAK2 with each receptor subunit using CTL-EN cell lines stably expressing GMRa alone ( Figure 4A ) or coexpressing GMRa and bc ( Figure 4B ) and observed that only bc coimmunoprecipitated JAK2. Second, we used the human erythroleukemic TF-1 cell line that endogenously expresses both receptor subunits and proliferates in response to GM-CSF to perform reverse experiments where JAK2 immunoprecipitation brought down bc but not GMRa ( Figure 4C ). Furthermore, following stimulation with GM-CSF, immunoprecipitation of bc brought down GMRa as well as phosphorylated JAK2, indicating that the JAK2 preassociated with bc only becomes phosphorylated after cytokine stimulation ( Figure 4C ). Finally, we studied human monocytes, a key effector cell type of the immune system and also observed JAK2 association with bc but not with GMRa ( Figure 4D ). Association of JAK2 with bc was observed in the absence of GM-CSF stimulation, and JAK2 binding and phosphorylation were upregulated following GM-CSF treatment. Similar results were observed with cells from a patient with acute myeloid leukemia and from purified human neutrophils ( Figure S5 ). The exclusive association of JAK2 with bc suggests that GMRa:bc heterodimerization is not sufficient for receptor activation and that JAK2 activation by GM-CSF requires functional bc dimerization as provided by the dodecamer.
Interfering with Site 4 Profoundly Affects Receptor Signaling
The dodecamer structure makes two important predictions that have physiological consequences for how GM-CSF engages its receptor and activates intracellular signaling. First, disruption of the Site 4 interaction is predicted to disturb dodecamer assembly and impede biological responses. Second, such disruption of Site 4 interactions should have little impact on hexamer assembly and so high-affinity binding should remain intact. We tested these possibilities by first mutating specific bc residues in Site 4 that were identified in the structure to make contact between hexamers. CTL-EN/IL3Ra/GMRa cells were stably transfected with plasmids encoding wild-type or mutant bc ( Figure 5A ) and then sorted for bc expression. The resulting stable pools were assayed for GM-CSF-and IL-3-mediated proliferation ( Figure 5B ). All cell lines showed an equivalent response to murine IL-2 (data not shown) that was used to normalize the proliferation responses. Mutation of residues 430-436 (M1) reduced Figure 4 . Association of JAK2 with bc but Not GMRa (A) JAK2 does not associate with GMRa in the CTL-EN/IL3Ra/GMRa cell line. CTL-EN/IL3Ra/GMRa were lysed and immunoprecipitated with antibodies specific for GMRa, for JAK2, or for an irrelevant control antigen. Immunoprecipitates were analyzed by western blotting using an antibody specific for JAK2 or GMRa. (B) JAK2 associates with bc but not GMRa in the CTL-EN/IL3Ra/GMRa/bc cell line. CTL-EN/IL3Ra/GMRa/bc were lysed and immunoprecipitated with antibodies specific for GMRa, bc, JAK2, or an irrelevant control antigen. Immunoprecipitates were analyzed by western blotting using an antibody specific for JAK2. (C) Phosphorylated JAK2 associates with bc but not GMRa in the hematopoietic cell line TF-1. TF-1 cells starved of GM-CSF for 18 hr were treated with 0 or 150 ng/ml GM-CSF for 5 min then lysed and immunoprecipitated with antibodies specific for GMRa, bc, JAK2, or an irrelevant control antigen. Immunoprecipitates were analyzed by western blotting using antibodies specific for GMR, bc, or phosphorylated JAK2. (D) JAK2 associates with bc but not GMRa in normal human monocytes and is phosphorylated only in the presence of GM-CSF. Cells were treated with 0 or 150 ng/ml GM-CSF for 5 min then lysed and immunoprecipitated with antibodies specific for GMRa or bc. Immunoprecipitates were analyzed by western blotting using antibodies specific for GMRa, bc, total JAK2, and phosphorylated JAK2 (pJAK2).
proliferation in response to GM-CSF (50-fold) and IL-3 (450-fold). Restoration of the buried tryptophan residue at 434 (M2) increased GM-CSF and IL-3 function, suggesting that the W434A substitution in M1 caused some degree of structural perturbation contributing to the loss of function. Mutation of residues 347-352, alone (M3) or combined with mutation of residues 354 and 362 (M5), had no effect on GM-CSF-mediated proliferation but caused a modest reduction in IL-3-mediated proliferation (10-fold). Combination of M2 and M3 (M4) virtually abolished proliferation in response to GM-CSF and IL-3, but additional mutation of residues 354 and 362 (M6) partially restored GM-CSF (C) GM-CSF-and IL-3-mediated cell signaling is reduced by mutation of bc Site 4 contact residues. CTL-EN/IL3Ra/GMRa cells expressing wild-type bc or the bc M1, M4, or M6 mutants were stimulated for 5 min with GM-CSF (upper panel) and IL-3 (lower panel) at 0, 0.15, 1.5, 15, or 150 ng/ml. Cells were lysed, immunoprecipitated with antibody specific for bc, then analyzed by western blotting using an anti-phosphotyrosine antibody (phos-Tyr) or an antibody specific for bc (Total bc). Cell lysates were analyzed by western blotting using antibodies specific for phosphorylated JAK2 (phos-JAK2) or phosphorylated STAT5 (phos-STAT5).
and IL-3 function ( Figure 5B ). Importantly, the strongest effect was observed with M4 that encompassed both targeted regions of the large area that forms Site 4 ( Figure 5A ). The IL-3 response is consistently more sensitive to mutation of Site 4 residues in bc than the GM-CSF response, but the overall hierarchy in mutant function is conserved between the two cytokines. CTL-EN cell lines expressing the bc mutants support high-affinity binding sites for GM-CSF and IL-3 (Table  S3 ), indicating that functional bc Sites 2 and 3 are retained by these mutants and that they are expressed on the cell surface. The reduced proliferation observed for cells expressing bcM1, bcM4, and bcM6 was accompanied by a greatly reduced ability of GM-CSF and IL-3 to stimulate tyrosine phosphorylation of bc, JAK2, and STAT5 ( Figure 5C ) and a substantial loss of colony-forming capacity (bcM1) in bone marrow cells stimulated with GM-CSF ( Figure S6 ). Functional disruption of Site 4 required multiple mutations, probably reflecting the large surface area of this protein-protein interface. Together, these data indicate that Site 4 residues predicted from the structure to be essential for dodecamer formation affect GM-CSF receptor activation. Furthermore, our results show that high-affinity binding (and hexamer assembly) is not sufficient for biochemical or functional receptor outputs and suggest that formation of a higher-order dodecamer complex is an obligate step for full receptor activation.
To determine the physiological significance of the dodecamer complex we generated antibodies specific to a portion of bc (residues 427-440) within Site 4 and assessed their ability to interfere with normal GM-CSF functions. Affinity-purified antibodies against the bc Site 4 peptide recognized the immunizing peptide as well as the soluble extracellular domains of bc ( Figure S7 ). We first examined GM-CSF upregulation of CD11b in neutrophils, a key component of the CD11b/CD18 (Mac-1) integrin responsible for integrin activation, neutrophil adhesion, leukocyte extravasation, and phagocytosis (Fagerholm et al., 2006) . Significantly, anti-bc Site 4 antibodies inhibited GM-CSF-mediated upregulation of CD11b expression in human neutrophils ( Figure 6A ). Furthermore, anti-bc Site 4 antibodies inhibited GM-CSF-mediated colony formation from bone marrow cells of a patient with chronic myelomonocytic leukemia (CMML), a condition where myeloid cells display a hypersensitive response to GM-CSF ( Figure 6B ). These results indicate that Site 4 is involved in normal as well as in immunopathological functions mediated by GM-CSF.
DISCUSSION
We present here the structure of a ligand:receptor complex in the GM-CSF/IL-3/IL-5 family of receptors and provide structural and functional evidence for an unexpected form of cytokine receptor assembly, namely a dodecamer, that can explain for the first time how these receptors are activated. The structure of the GM-CSF receptor complex reveals a hexamer with a stoichiometry of 2 GM-CSF:2 GMRa:2 bc, in an arrangement analogous to other heteromeric cytokine receptors and using three sites of interaction (Figure 2 ). Site 1 is formed largely by helix D of GM-CSF interacting with domains 1 and 2 of GMRa. Site 2 is largely provided by helix A of GM-CSF interacting with a composite bc surface comprising the A-B and E-F loops of domain 1 from one bc chain and the B-C and F-G loops of domain 4 of the second bc chain. This elbow region resembles the ligand-binding interface conserved in the simpler two-domain hematopoietin receptors, despite domains 1 and 4 being noncontiguous. The composite nature of the interface formed between GM-CSF and the bc dimer is highly unusual. In other ternary cytokine-cytokine receptor complexes different regions of the cytokine interact with just one receptor chain (Figure 2 ). More generally, we haven't been able to identify known examples of nonobligate heterotrimers that involve an obligate dimer in which different surfaces of each component interact with each other. The key to the Site 2 interaction is a hydrogen bond formed between E21 of GM-CSF and Y421 in bc that is consistent with mutagenesis studies that highlight the importance of these residues for GM-CSF binding and function (Hercus et al., 1994a; Woodcock et al., 1996) . Mutagenesis studies suggest that structurally similar interactions are likely to exist between Y421 of bc and E22 of IL-3 and E13 of IL-5 (Barry et al., 1994; Tavernier et al., 1995 . Site 3 is formed between domain 2 of GMRa and domain 4 of bc and serves to stabilize the cytokine-mediated heterodimerization.
We observed a higher-order dodecamer complex composed of two hexamers that interact through a Site 4 surface and bring the membrane-proximal domains of bc and GMRa into close proximity (Figure 3) . The functional significance of the dodecamer complex is supported first by the observation that JAK2, which is essential for GM-CSF signaling, is associated with bc and not GMRa (Figure 4 ). This could be seen in transfected cells, in hemopoietic cell lines that respond to GM-CSF using endogenous GM-CSF receptors, and, most importantly, in primary human monocytes and neutrophils, essential leukocytes that participate in immunity. Thus JAK2-associated bc as a homodimer in the unliganded receptor (Muto et al., 1996; Stomski et al., 1996; Carr et al., 2001) or as a heterodimer with GMRa in the hexamer complex (Figure 1 ) would be too far apart (120 Å ) to transphosphorylate the receptor. The dodecamer structure (Figure 3) on the other hand, brings JAK2-associated bc close enough (10 Å ) to allow functional dimerization and transphosphorylation of the receptor and initiation of signal transduction. Second, (A) Affinity-purified antibodies to bc Site 4 residues inhibit upregulation of CD11b in human neutrophils treated with GM-CSF. Histograms shows relative fluorescence for CD11b staining on neutrophils either unstimulated (black) or GM-CSFstimulated in the presence of nil (red) or 4 mg/ml (blue) of affinity-purified bc Site 4 antibody. Preincubation with 1 mg/ml of an irrelevant control antibody (dashed line) had no effect on CD11b expression by unstimulated (black) or GM-CSFstimulated (red) neutrophils. (B) Affinity-purified antibodies to bc Site 4 residues inhibit GM-CSF-stimulated colony formation by bone marrow cells from a patient with chronic myelomonocytic leukemia (CMML). Bone marrow mononuclear cells (1 3 10 5 ) from a patient with CMML were plated in 2 ng/ml GM-CSF plus medium (Nil), or plus 10 mg/ml bc Site 4 antibody (Site 4 Ab), or plus 0.5 mg/ml of a control bc antibody (Control Ab). Data show average of triplicate plates and error bars represent the standard error of the mean (SEM). The twotailed p value was generated using an unpaired t test.
several mutants across the Site 4 interface decreased biological activity and signaling with M4 showing an almost complete elimination of function while not affecting high-affinity binding (Figure 5) . Third, antibodies directed against part of bc Site 4 significantly reduced GM-CSF-mediated upregulation of the integrin CD11b in human neutrophils and stimulation of the growth and differentiation of leukemic cells ( Figure 6 ). Assembly of the dodecamer complex also promotes the interaction of two GMRa chains. While bc is the principal signaling component of the GM-CSF/IL-3/IL-5 receptor family, it is clear that the cytoplasmic domains of alpha chains are essential for signal transduction (Muto et al., 1995; Lia et al., 1996; Lilly et al., 2001) . The observation that GMRa lacking a cytoplasmic domain acts in a dominant-negative fashion (Lia et al., 1996) indicates that the signaling complex must contain at least two GMRa chains. In the dodecamer complex the GMRa cytoplasmic tails are 30 Å from the bc cytoplasmic tails of each neighboring hexamer ( Figure 3A) , thus also providing a structural explanation for how the cytoplasmic domain of GMRa can participate in signaling.
In analyzing the role of Site 4 in receptor activation we focused largely on two regions of bc, residues 344-365 and 427-438, because their side chains are located in close proximity on the surface of bc ( Figure 5A ). Interestingly, alanine substitution mutants targeting only one of these regions at a time had little impact on GM-CSF function ( Figure 5B ). The mutations with the greatest effect on GM-CSF function, M4 and M6, encompassed both regions of Site 4, suggesting that many residues in Site 4 contribute to the function of this interacting surface.
While we have not examined the effect of bc Site 4 mutations on IL-5 function, the IL-5 dimer can be docked into our dodecamer structure ( Figure S8 ), suggesting that IL-5 is capable of assembling a dodecamer complex. This particular assembly may also allow the simultaneous incorporation of different cytokines bound to the cognate alpha chain, potentially explaining how stimulation of cells with IL-3 or IL-5 can result in phosphorylation of the GM-CSF receptor . The structural and functional data shown here support a model of GM-CSF/IL-3/IL-5 receptor activation where the hexamer complex provides for high-affinity cytokine binding but the dodecamer complex is required for receptor activation and signal transduction (Figure 7) . Interestingly, the different mutations of bc at the Site 4 interface greatly reduced signaling and function not only from GM-CSF but also from IL-3 ( Figure 5 ), suggesting that dodecamer formation may be a conserved mechanism utilized by the whole GM-CSF/IL-3/IL-5 receptor family. As such it may offer new avenues to interfere with receptor activation and facilitate the development of new molecules, which by simultaneously blocking GM-CSF, IL-3, and IL-5 function may be of clinical use in diseases where all these cytokines play a pathogenic role.
EXPERIMENTAL PROCEDURES Expression and Purification of Receptor Components
Soluble human GM-CSF was produced in Escherichia coli (Hercus et al., 1994a) . The soluble extracellular domains of GMRa or bc were expressed in Sf21 insect cells and purified by affinity chromatography (McClure et al., 2003) .
Structure Determination of the Complex
Ternary complex consisting of GM-CSF, sGMRa, and sbc was concentrated to 5 mg/ml in 10 mM HEPES (pH 7.0). The best crystals were grown from a solution containing 100 mM HEPES buffer (pH 7.0), 6% (v/v) PEG3350, 0.2 M proline at 20 C using the hanging drop technique. The crystals belonged to the space group P6 3 22 with unit cell dimensions a = b = 166.4 Å and c = 212.2 Å . Diffraction data were collected on the BioCARS beamline 14-BM-C at the Advanced Photon Source (Chicago, IL, USA) ( Table S1 ). The structure was determined by molecular replacement using the known structure of isolated bc (Carr et al., 2001 ) and refined at 3.3 Å resolution (Supplemental Data).
Mutagenesis and Generation of Cell Lines
Mutations of bc were generated by site-directed mutagenesis using the Altered site system (Promega). Wild-type and Site 4 mutant bc cDNAs were subcloned into the expression vector pRcCMVpuro . Murine CTL-EN cells (Jenkins et al., 1999) stably expressing human IL3Ra and GMRa chains (CTL-EN/IL3Ra/GMRa) were grown routinely in RPMI 1640 medium supplemented with 10% v/v FCS, 2 mM glutamine, 50 mM mercaptoethanol, and 100 U/ml mIL-2. TF-1 cells were maintained as previously described (Hercus et al., 1994a) . CTL-EN/IL3Ra/GMRa cells (5 3 10 6 ) were electroporated with 20 mg of pRcCMVpuro DNA encoding wild-type or Site 4 mutant bc at 960 mF with 270 V and selected in 2-5 mg/ml puromycin 48 hr after transfection. Following selection, pools of cells were sorted for bc expression by flow cytometry using indirect immunofluorescence staining as previously described on a FACSAria (Becton Dickinson). Cells were starved of growth
Figure 7. Model of Signal Transduction
The low-affinity complex consists of GM-CSF bound to GMRa. Interaction with free bc forms the high-affinity hexamer complex. Dodecamer (or higher-order) complexes form by lateral aggregation of hexamer complexes to form a fully competent signaling complex. JAK2 associated with bc (shown as red spheres) is able to dimerize and transphosphorylate in the dodecamer complex but not in the hexamer complex.
factor overnight prior to use, and for biochemical studies, starve medium included 0.5% v/v FCS.
Receptor Binding Assays
Radio-iodinated GM-CSF and IL-3 binding assays to CTL-EN/IL3Ra/GMRa cell lines stably expressing wild-type bc or bc Site 4 mutants were as previously described (Woodcock et al., 1994) . COS cells were cotransfected with plasmids encoding GMRa and IL3Ra together with wild-type or bc Site 2 mutants by electroporation and saturation binding assays with radio-iodinated cytokine carried out in 24 well plates as previously described . Dissociation constants were determined using Prism (Graphpad Software).
Cell Proliferation Assays
Starved CTL-EN/IL3Ra/GMRa cell lines stably expressing wild-type bc or bc Site 4 mutants were incubated (1 3 10 4 cells per well) with growth factors over a range of concentrations for 40 hr. Cells were pulsed with 0.25 mCi/ well of [6-3 H]-thymidine (GE-Healthcare) for 4 hr, harvested onto glass fiber filters, and counted in liquid scintillation fluid on a Top Count NXT (Perkin Elmer).
Immunoprecipitations and Immunoblotting
Human mononuclear cells from normal donors were isolated by Ficoll-Hypaque density-gradient centrifugation and resuspended in PBS containing 0.1% human albumin (CSL). CTL-EN/IL3Ra/GMRa and CTL-EN/IL3Ra/ GMRa/bc cells were lysed and immunoprecipitated using 4H1 anti-GMRa monoclonal antibody , 1C1 anti-bc monoclonal antibody (Stomski et al., 1996) , anti-JAK2 monoclonal antibody (Cell Signaling), or 12CA5 anti-influenza hemagglutinin monoclonal antibody. Samples from 2 3 10 7 cells were subjected to western blotting with antibodies specific for GMRa or total JAK2. Human monocytes, starved TF-1 cells, or starved CTL-EN/IL3Ra/GMRa/bc cells were stimulated with 0 or 150 ng/ml GM-CSF for 5 min, lysed, and immunoprecipitated using 4H1, 1C1, anti-JAK2, or 12CA5 monoclonal antibodies. Samples were subjected to western blotting with antibodies specific for GMRa, bc, total JAK2, or tyrosine-phosphorylated JAK2. Starved CTL-EN/IL3Ra/GMRa cell lines stably expressing wild-type bc or bc Site 4 mutants were stimulated with 0, 0.15, 1.5, 15, or 150 ng/ml GM-CSF or IL-3 for 5 min, lysed, and immunoprecipitated using the 1C1 anti-bc monoclonal antibody. Samples of bc immunoprecipitates were subjected to western blotting with 1C1 anti-bc or 4G10 anti-phosphotyrosine monoclonal antibodies (Upsate Cell Signaling Solutions). Samples of cell lysates were subjected to western blotting with antibodies specific for phosphorylated JAK2 or phosphorylated STAT5.
Generating and Functional Testing of Polyclonal Antibodies against bc Site 4 Antibodies directed to bc Site 4 were generated by immunizing New Zealand white rabbits with a peptide (EWSEARSWDTESVL) spanning residues 427-440 of bc (Mimotopes) and conjugated to keyhole limpet antigen. Peptide-specific polyclonal antibody was affinity purified using the EWSEARSWDTESVL peptide coupled to Sepharose. CD11b expression on neutrophils was monitored as previously described (Guthridge et al., 2006) but included a 30 min preincubation with antibody at 4 C followed by a 30 min incubation with 15 ng/ml GM-CSF at 37 C. The 12CA5 monoclonal antibody was used as a negative control. Bone marrow colony assays where performed as previously described (Ramshaw et al., 2002) with the 1C1 monoclonal antibody used as a negative control.
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